Corbus Pharmaceuticals Holdings Inc (CRBP) was Initiated by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $17. Cantor Fitzgerald advised their investors in a research report released on Oct 5, 2016.
Corbus Pharmaceuticals Holdings Inc opened for trading at $7 and hit $7.03 on the upside on Tuesday, eventually ending the session at $7.02, with a gain of 2.18% or 0.15 points. The heightened volatility saw the trading volume jump to 5,37,690 shares. Company has a market cap of $307 M.
In a different news, on Sep 8, 2016, Sean F. Moran (CFO) purchased 30,800 shares at $5.12 per share price. According to the SEC, on Aug 22, 2016, David P Hochman (director) purchased 1,800 shares at $3.77 per share price. On Aug 18, 2016, Barbara White (Chief Medical Officer) purchased 38,000 shares at $3.15 per share price, according to the Form-4 filing with the securities and exchange commission.
Corbus Pharmaceuticals Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare life-threating inflammatory-fibrotic diseases. The Company’s lead product candidate Resunab is an oral anti-inflammatory drug that is being developed for the treatment of inflammatory disorders such as cystic fibrosis (CF) and scleroderma. The Company has completed the Phase I safety studies for the treatment of scleroderma and cystic fibrosis. The Company has submitted an Investigational New Drug Application (INDA) to the United States Food and Drug Administration (FDA) for a Phase IIa double-blind placebo controlled clinical study evaluating Resunab in patients with diffuse scleroderma. Pre-clinical and Phase I clinical studies (123 subjects) have shown Resunab to have a favorable safety profile coupled with suitable potency in pre-clinical models of inflammation and fibrosis.